{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3"},{"groupId":"OG001","value":"73.1"}]}],"title":"no decrease or decrease < 10%, still above LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"3.1"}]}],"title":"decrease < 10%, below lower limit of normal (LLN)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"15.4"}]}],"title":"decrease 10-15%, still above lower limit of normal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"0.8"}]}],"title":"decrease 10-15%, below lower limit of normal (LLN)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"6.9"}]}],"title":"decrease > 15%, still above lower limit of normal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0"},{"groupId":"OG001","value":"0.8"}]}],"title":"decrease > 15%, below lower limit of normal (LLN)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"description":"The summary of asymptomatic changed in LVEF.","groups":[{"description":"Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies","id":"OG000","title":"FEC-75 Then Paclitaxel/Trastuzumab"},{"description":"Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies","id":"OG001","title":"Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75"}],"paramType":"NUMBER","populationDescription":"All patients who had a MUGA or ECHO performed at week 24 are included in the summary of asymptomatic changed in LVEF at week 24.","reportingStatus":"POSTED","timeFrame":"Baseline, at 24 week","title":"Asymptomatic Decreases From Baseline in LVEF at Week 24","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}